Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025

Reuters

09/03

Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, has announced upcoming presentations of their clinical data at the European Society for Medical Oncology (ESMO) Congress 2025. The presentations will include the first clinical data from KO-2806, a next-generation farnesyltransferase inhibitor $(FTI)$, highlighting its potential in addressing resistance mechanisms in cancer. The data will be shared through three posters, detailing the outcomes of various trials. The presentations cover a phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma, KO-2806 as a monotherapy for advanced solid tumors, and a combination study of Tipifarnib and alpelisib for head and neck squamous cell carcinoma. All results are scheduled to be presented at the congress, with further insights to be discussed in a virtual event hosted by Kura Oncology on October 18, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9522362-en) on September 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564398740"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564398740\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564398740?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564398740","market":"us","top_or_hot":-1,"title":"Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KURA\">Kura Oncology, Inc</a>., a clinical-stage biopharmaceutical company, has announced upcoming presentations of their clinical data at the European Society for Medical Oncology (ESMO) Congress 2025. The presentations will include the first clinical data from KO-2806, a next-generation farnesyltransferase inhibitor <a href=\"https://laohu8.com/S/FTI\">$(FTI)$</a>, highlighting its potential in addressing resistance mechanisms in cancer. The data will be shared through three posters, detailing the outcomes of various trials. The presentations cover a phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma, KO-2806 as a monotherapy for advanced solid tumors, and a combination study of Tipifarnib and alpelisib for head and neck squamous cell carcinoma. All results are scheduled to be presented at the congress, with further insights to be discussed in a virtual event hosted by Kura Oncology on October 18, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9522362-en) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-03 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KURA\">Kura Oncology, Inc</a>., a clinical-stage biopharmaceutical company, has announced upcoming presentations of their clinical data at the European Society for Medical Oncology (ESMO) Congress 2025. The presentations will include the first clinical data from KO-2806, a next-generation farnesyltransferase inhibitor <a href=\"https://laohu8.com/S/FTI\">$(FTI)$</a>, highlighting its potential in addressing resistance mechanisms in cancer. The data will be shared through three posters, detailing the outcomes of various trials. The presentations cover a phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma, KO-2806 as a monotherapy for advanced solid tumors, and a combination study of Tipifarnib and alpelisib for head and neck squamous cell carcinoma. All results are scheduled to be presented at the congress, with further insights to be discussed in a virtual event hosted by Kura Oncology on October 18, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9522362-en) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL9PDBXT:1","article_id":"2564398740","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564398740","pubTimestamp":1756900968,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on September 03, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4505":"高瓴资本持仓","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","KURA":"Kura Oncology, Inc","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Kura Oncology在2025年ESMO大会上公布下一代法尼基转移酶抑制剂KO-2806的首个临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURA":0.9,"NDAQ":0.9},"content_text":"Kura Oncology Announces First Clinical Data from Next-Generation Farnesyl Transferase Inhibitor KO-2806 at ESMO Congress 2025\n    \n\nKura Oncology, Inc., a clinical-stage biopharmaceutical company, has announced upcoming presentations of their clinical data at the European Society for Medical Oncology (ESMO) Congress 2025. The presentations will include the first clinical data from KO-2806, a next-generation farnesyltransferase inhibitor $(FTI)$, highlighting its potential in addressing resistance mechanisms in cancer. The data will be shared through three posters, detailing the outcomes of various trials. The presentations cover a phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma, KO-2806 as a monotherapy for advanced solid tumors, and a combination study of Tipifarnib and alpelisib for head and neck squamous cell carcinoma. All results are scheduled to be presented at the congress, with further insights to be discussed in a virtual event hosted by Kura Oncology on October 18, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9522362-en) on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}